VSTM - Verastem, Inc.
Pre-Market:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 12.05 |
| Open | 12.00 |
| Bid | 11.57 x 1100 |
| Ask | 12.78 x 1300 |
| Day's Range | 11.22 - 13.25 |
| 52 Week Range | 3.48 - 17.64 |
| Volume | |
| Avg. Volume | 220,781 |
| Market Cap | 193.34M |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.26 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.00 |
Fair Value
Related Research
Business WireVerastem Oncology Announces Reverse Stock Split
BOSTON, May 31, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock. Verastem’s stockholders approved an amendment to Verastem’s Restated Certificate of Incorporation (as amended, the "Amended Charter") to effect the reverse stock split at Verastem’s Annual Meeting of Stockholders held on May 15, 2023. The re
- Business Wire
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
BOSTON, May 25, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from Part A of the ongoing registration-directed RAMP 201 (ENGOTov60/GOG3052) trial evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
Business WireVerastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
BOSTON, May 16, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023. Dr. Tollefson is the Senior Vice President and Head of Global Medical Affairs at Seagen Inc. where she has led the medical organization through the successful launches of three practice-changing medicines and established a global medical affairs organi
Business WireVerastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, May 09, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent progress.
Simply Wall St.Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss
It's nice to see the Verastem, Inc. ( NASDAQ:VSTM ) share price up 15% in a week. But will that repair the damage for...
- Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 01, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
Business WireNew Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
BOSTON, April 26, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib (VS-6766) and defactinib in patients with low-grade serous ovarian cancer (LGSOC) has been selected for a presentation in a Poster Discussion Session at the upcoming American Society
Business WireVerastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
BOSTON, April 18, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30 p.m. ET.
InvestorPlace7 Very Undervalued Penny Stocks to Buy in April 2023
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price. It is also worth noting that penny stocks are highly risky and it goes without saying that losses aren’t uncommon. In other words, don’t treat these stocks the same as their more stable counterparts, and only invest what you can afford to lose. That said, the penny stocks listed here are interesting and fall, for the most
Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 06, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 17,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an
Business WireNew Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
BOSTON, March 15, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer (HGSOC), tips and resources, and ways to connect with others
- Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
BOSTON, March 14, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.
- Business Wire
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
BOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
ZacksVerastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac
- Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC). The Company is also providing a
- Simply Wall St.
individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week
A look at the shareholders of Verastem, Inc. ( NASDAQ:VSTM ) can tell us which group is most powerful. We can see that...
- Business Wire
Verastem Oncology Appoints Rob Gagnon to Board of Directors
BOSTONBOSTON, December 15, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022. Mr. Gagnon is the Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund and the former Chief Business Officer and Chief Financial Officer at Verastem Oncology.
- Simply Wall St.
Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)
Verastem ( NASDAQ:VSTM ) Third Quarter 2022 Results Key Financial Results Net loss: US$18.1m (loss narrowed by 21% from...
- Business Wire
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, November 03, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
- Business Wire
Verastem Oncology Appoints Anil Kapur to Board of Directors
BOSTON, October 20, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022. Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation.
- Business Wire
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
BOSTON, October 04, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek Program) clinical trials.
Insider Monkey10 Long-Term Stocks to Buy During Recessions
In this article, we discuss the 10 long-term stocks to buy during recessions. If you want to read about some more stocks to buy during recessions, go directly to 5 Long-Term Stocks to Buy During Recessions. Over the past few weeks, there had been renewed optimism on Wall Street that the central bank would succeed […]
- Simply Wall St.
Investors five-year losses grow to 64% as the stock sheds US$34m this past week
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
- Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, August 08, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.